Fairvalue-Calculator Fairvalue-Calculator
EN DE

TWi Biotechnology, Inc (6610) Fair Value & Analysis

Healthcare · TW · Market cap 5.5B TWD

Price27.05 TWD
Fair Value9.20 TWD
Upside-66.0%
Quality95/100
Evidence: Low Range 6.90 TWD – 11.50 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

TWi Biotechnology, Inc (6610) currently trades at 27.05 TWD, while our model-based Fair Value estimate is 9.20 TWD — implying the stock looks roughly 66.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseases. It has a drug development agreement with Hong Kong Winhealth Pharma Group Co., Limited. in Mainland China, Hong Kong, and Macao markets. TWi Biotechnology, Inc. was founded in 2010 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is TWi Biotechnology, Inc (6610) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 9.20 TWD versus a price of 27.05 TWD — about −66% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6610?
Our 21-model fair value for TWi Biotechnology, Inc is 9.20 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 27.05 TWD.
What is the quality score of 6610?
TWi Biotechnology, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.